HR+/HER2- BREAST CANCER
Clinical trials for HR+/HER2- BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR+/HER2- BREAST CANCER trials appear
Sign up with your email to follow new studies for HR+/HER2- BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
First human trial begins for new cancer pill targeting advanced tumors
Disease control Recruiting nowThis is the first study in people to test a new oral pill called NKT5097 for adults with advanced or metastatic solid tumors, with a focus on certain breast, ovarian, and uterine cancers. The main goals are to find a safe dose and understand the side effects. Researchers will als…
Matched conditions: HR+/HER2- BREAST CANCER
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New pill targets Hard-to-Treat cancers in first human trial
Disease control Recruiting nowThis is the first study in people for a new oral medication called AVZO-021. It aims to find a safe dose and see if the drug can help control advanced solid tumors, including certain types of breast and ovarian cancer, when other standard treatments are no longer working. The stu…
Matched conditions: HR+/HER2- BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Avenzo Therapeutics, Inc. • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New drug combo aims to shrink tumors before breast cancer surgery
Disease control Recruiting nowThis study is testing whether adding an experimental drug called QL1706 to standard chemotherapy works better than chemotherapy alone when given before surgery for a common type of breast cancer (HR+/HER2-). It will involve 238 women to see if the combination helps eliminate all …
Matched conditions: HR+/HER2- BREAST CANCER
Phase: PHASE2 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated Mar 05, 2026 13:59 UTC
-
New pill targets advanced breast cancer in First-Ever human trial
Disease control Recruiting nowThis is the first human study testing a new oral medication called AVZO-023 for patients with advanced solid tumors, focusing on a common type of breast cancer. The trial aims to find the safest and most effective dose, first by giving AVZO-023 alone, and then in combination with…
Matched conditions: HR+/HER2- BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Avenzo Therapeutics, Inc. • Aim: Disease control
Last updated Mar 02, 2026 15:21 UTC
-
Tracking promising cancer drugs in real patients
Knowledge-focused Recruiting nowThis study aims to collect real-world information about how well FDA-approved antibody-drug conjugate (ADC) treatments work for people with advanced HER2-negative breast cancer. Researchers will follow 100 patients receiving these treatments as part of their regular care to under…
Matched conditions: HR+/HER2- BREAST CANCER
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Mar 18, 2026 14:41 UTC